Combining cabozantinib, nivolumab and ipilimumab in advanced hepatocellular carcinoma: does benefit outweigh toxicity?
Chinese Clinical Oncology · 2024
DOI: 10.21037/cco-23-106 ↗Kurz gefasst
Editorial in der Zeitschrift Chinese Clinical Oncology, 2024. Verfasst von Thiago A Miranda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hospital Sírio-Libanês, Brasília, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Nivolumab, Pyridines.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Hospital Sírio-Libanês, Brasília, Brazil.
- Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Zitieren
APA
Miranda, T. A., Girardi, D. M., & Pereira, A. A. L. (2024). Combining cabozantinib, nivolumab and ipilimumab in advanced hepatocellular carcinoma: does benefit outweigh toxicity?. Chinese Clinical Oncology. https://doi.org/10.21037/cco-23-106
Vancouver
Miranda TA, Girardi DM, Pereira AAL. Combining cabozantinib, nivolumab and ipilimumab in advanced hepatocellular carcinoma: does benefit outweigh toxicity?. Chinese Clinical Oncology. 2024. doi:10.21037/cco-23-106
BibTeX
@article{Miranda2024,
author = {Miranda, Thiago A and Girardi, Daniel M and Pereira, Allan A L},
title = {Combining cabozantinib, nivolumab and ipilimumab in advanced hepatocellular carcinoma: does benefit outweigh toxicity?},
journal = {Chinese Clinical Oncology},
year = {2024},
doi = {10.21037/cco-23-106}
}
EUVIMED